Zydus Lifesciences gets final nod to manufacture, market Sucralfate Tablets

05 May 2023 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Sucralfate Tablets USP, 1 gram (USRLD: Carafate Tablets, 1 gram). Sucralfate is used to treat and prevent ulcers in the intestines by forming a coating over ulcers, protecting the area from further injury. This helps ulcers heal more quickly. The drug will be manufactured at the group’s topical manufacturing facility at SEZ, Ahmedabad (India).

Sucralfate Tablets USP, 1 gram had annual sales of $84 million in the United States (IQVIA MAT February 2023). The group now has 367 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

864.55 -3.25 (-0.37%)
19-Jan-2026 11:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1666.70
Dr. Reddys Lab 1168.55
Cipla 1380.05
Zydus Lifesciences 864.55
Lupin 2175.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×